Literature DB >> 4007043

Hydroxychloroquine in human breast milk.

M Ostensen, N D Brown, P K Chiang, J Aarbakke.   

Abstract

Hydroxychloroquine 3.2 micrograms was detected in breast milk from a woman given 800 mg over 48 hour.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4007043     DOI： 10.1007/bf00543338

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  1 in total

1.  Determination of chloroquine and its de-ethylated metabolites in human plasma by ion-pair high-performance liquid chromatography.

Authors:  N D Brown; B T Poon; J D Chulay
Journal:  J Chromatogr       Date:  1982-04-16
  1 in total
  7 in total

Review 1.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

3.  Piroxicam in breast milk after long-term treatment.

Authors:  M Ostensen; I Matheson; H Laufen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

5.  Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Authors:  Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade
Journal:  J Cutan Med Surg       Date:  2018-11-21       Impact factor: 2.092

Review 6.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

Review 7.  Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Authors:  Melanie R Nicol; Abhay Joshi; Matthew L Rizk; Philip E Sabato; Radojka M Savic; David Wesche; Jenny H Zheng; Jack Cook
Journal:  Clin Pharmacol Ther       Date:  2020-09-01       Impact factor: 6.903
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.